Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Gelteq Ltd. (GELS:NASDAQ), powered by AI.
Gelteq Ltd. is currently trading at $1.53. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Gelteq Ltd. on Alpha Lenz.
View Gelteq Ltd.'s valuation metrics on Alpha Lenz.
“Gelteq Ltd.'s ROE is -43.0%. Explore profitability and growth together.”
Ask for details →Gelteq Ltd. is a biopharmaceutical company focused on developing and commercializing innovative gel-based formulations for various therapeutic applications. At its core, Gelteq specializes in transforming traditional oral and injectable medications into more convenient gel formats, potentially enhancing patient compliance and drug efficacy. The company operates within the healthcare and pharmaceuticals sector, targeting conditions that require precise dosing and improved delivery mechanisms. One of Gelteq’s notable features is its application of proprietary gel technology across a range of therapeutic areas, including pain management and chronic disease treatment. This technology can enhance drug absorption and provide alternative administration routes, offering potential benefits for both healthcare providers and patients. In the financial market, Gelteq Ltd. plays a role as a niche player in the biopharmaceutical industry, providing innovative solutions that could meet unmet medical needs. The company's focus on reformulating existing drugs can shorten development timelines and reduce risk compared to novel drug candidates, marking its significance in a competitive landscape where effective delivery solutions are increasingly valued.
“Gelteq Ltd.'s ROE is -43.0%. Explore profitability and growth together.”
Ask for details →Gelteq Ltd. (ticker: GELS) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 7 employees.
The current price is $1.53 with a P/E ratio of -x and P/B of -x.
ROE is -42.99% and operating margin is -2988.98%. Annual revenue is $165,645.